{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.07","value":"-0.06"},{"groupId":"OG001","spread":"0.10","value":"0.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"441"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"description":"A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). The overall change is based on the estimated main treatment effect. Least square (LS) Mean value was controlled for Treatment, visit, Treatment\\*Visit and baseline.","dispersionType":"Standard Error","groups":[{"description":"Abemaciclib 150 mg administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG000","title":"Abemaciclib + Fulvestrant"},{"description":"Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug with a baseline and at least 1 post-baseline result.","reportingStatus":"POSTED","timeFrame":"Baseline, End of Study (Up To 31 Months)","title":"Change From Baseline in Pain and Symptom Burden Assessment Using the Modified Brief Pain Inventory-Short Form (mBPI-sf)","type":"SECONDARY","unitOfMeasure":"score on a scale"}